Back to top
more

Guardant Health (GH)

(Real Time Quote from BATS)

$29.71 USD

29.71
332,918

-0.50 (-1.66%)

Updated Nov 15, 2024 11:38 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Charles River (CRL) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

The acquisitions of Vigene Biosciences and Cognate are likely to have a full-quarter favorable impact on Charles River's (CRL) Q4 Manufacturing Support revenues.

LabCorp (LH) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

LabCorp's (LH) Covance Drug Development Q4 results are expected to reflect an increase in organic revenues on base business growth and contribution from COVID testing performed through the central lab.

CVS Health (CVS) Q4 Earnings to Gain From COVID Vaccine Sales

by Zacks Equity Research

CVS Health (CVS) is expected to have seen a significant part of its specialty orders being placed digitally through Q4 months, with growth drivers being COVID testing, vaccines and omni-channel.

Zimmer Biomet (ZBH) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Zimmer Biomet (ZBH) struggles to sustain the recovery trend in the second half of 2021.

What's in Store for Quest Diagnostics (DGX) in Q4 Earnings?

by Zacks Equity Research

In Q4, Quest Diagnostics' (DGX) non-COVID base business might have registered a year-over-year sales rebound.

What's in Store for Boston Scientific's (BSX) Q4 Earnings?

by Zacks Equity Research

On a geographic basis, every Boston Scientific (BSX) market in fourth-quarter 2021 is expected to have registered broad-based growth compared with the dull fourth-quarter 2020 numbers.

After Plunging 27.6% in 4 Weeks, Here's Why the Trend Might Reverse for Guardant Health (GH)

by Zacks Equity Research

Guardant Health (GH) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Guardant Health (GH) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Guardant Health (GH) delivered earnings and revenue surprises of -17.78% and 2.76%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Why Earnings Season Could Be Great for Guardant Health (GH)

by Zacks Equity Research

Guardant Health (GH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Guardant Health (GH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Guardant Health (GH) delivered earnings and revenue surprises of -10.34% and 8.82%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Kevin Cook headshot

Bear of the Day: NeoGenomics (NEO)

by Kevin Cook

Emerging diagnostics provider is steadily growing sales and key M&A but ran into an EPS cliff

Earnings Preview: Guardant Health (GH) Q2 Earnings Expected to Decline

by Zacks Equity Research

Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kevin Cook headshot

Bull of the Day: Exact Sciences (EXAS)

by Kevin Cook

EPS surprises abound as Cologuard and Precision Oncology grow sales 20% into next year

New Strong Sell Stocks for July 7th

by Zacks Equity Research

ACCD, DNLI, FSLY, FHB and GH have been added to the Zacks Rank #5 (Strong Sell) List on July 7, 2021.

J&J's (JNJ) Amivantamab Gets FDA Nod for Rare Lung Cancer

by Zacks Equity Research

With the FDA nod, J&J's (JNJ) Rybrevant becomes the first fully-human, bispecific antibody approved for the treatment of patients with NSCLC that targets EGFR exon 20 insertion mutations.

Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Guardant Health (GH) delivered earnings and revenue surprises of 40.24% and 5.85%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Guardant Health (GH) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kevin Cook headshot

Bear of the Day: Guardant Health (GH)

by Kevin Cook

Cancer detection innovator with liquid biopsy saw analysts slash estimates as R&D investment costs rise

New Strong Sell Stocks for March 29th

by Zacks Equity Research

HTHT, FNLPF, GMRE, THRY, and GH have been added to the Zacks Rank #5 (Strong Sell) List on March 29, 2021

New Strong Sell Stocks for March 1st

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Analysts Estimate Guardant Health (GH) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Guardant Health (GH) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Guardant Health (GH) delivered earnings and revenue surprises of -129.41% and 12.18%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Guardant Health (GH) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kevin Cook headshot

7 Diagnostic and Genomic Stocks Storming Into October

by Kevin Cook

COVID-19 has created an Apollo Mission status for advanced medical technologies and smart investors are profiting.